Voya Investment Management LLC Acquires 67,559 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Voya Investment Management LLC raised its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 9.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 796,684 shares of the company's stock after buying an additional 67,559 shares during the quarter. Voya Investment Management LLC owned about 1.07% of SpringWorks Therapeutics worth $28,784,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of SWTX. Huntington National Bank raised its position in shares of SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock valued at $25,000 after acquiring an additional 192 shares in the last quarter. AlphaQuest LLC lifted its position in shares of SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock worth $36,000 after buying an additional 414 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in shares of SpringWorks Therapeutics in the 4th quarter valued at about $45,000. KBC Group NV grew its position in shares of SpringWorks Therapeutics by 59.1% during the 4th quarter. KBC Group NV now owns 2,634 shares of the company's stock valued at $95,000 after buying an additional 978 shares during the last quarter. Finally, US Bancorp DE raised its stake in SpringWorks Therapeutics by 56.0% during the fourth quarter. US Bancorp DE now owns 4,336 shares of the company's stock worth $157,000 after acquiring an additional 1,556 shares during the period.

Analysts Set New Price Targets

Several research firms have recently commented on SWTX. TD Cowen reaffirmed a "hold" rating and set a $47.00 target price (down from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday. HC Wainwright reaffirmed a "neutral" rating and issued a $47.00 target price (down from $74.00) on shares of SpringWorks Therapeutics in a research report on Wednesday. Barclays reissued an "equal weight" rating and set a $47.00 price target (down previously from $63.00) on shares of SpringWorks Therapeutics in a report on Monday. Cowen cut shares of SpringWorks Therapeutics to a "hold" rating in a research report on Tuesday. Finally, Wedbush restated a "neutral" rating and issued a $47.00 price target (down previously from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, SpringWorks Therapeutics currently has an average rating of "Hold" and a consensus price target of $52.57.

Insider Buying and Selling at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, COO Badreddin Edris sold 20,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $54.23, for a total transaction of $1,084,600.00. Following the completion of the sale, the chief operating officer now directly owns 169,712 shares of the company's stock, valued at approximately $9,203,481.76. This represents a 10.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Bhavesh Ashar sold 1,016 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $61.19, for a total transaction of $62,169.04. Following the sale, the insider now owns 62,053 shares in the company, valued at $3,797,023.07. This represents a 1.61 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 440,766 shares of company stock valued at $24,402,956. Corporate insiders own 7.83% of the company's stock.

SpringWorks Therapeutics Price Performance

Shares of SpringWorks Therapeutics stock traded down $0.09 on Thursday, hitting $46.21. The company had a trading volume of 6,435,174 shares, compared to its average volume of 1,893,096. The company has a market cap of $3.47 billion, a PE ratio of -13.28 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 52 week low of $28.21 and a 52 week high of $62.00. The business has a 50-day simple moving average of $45.49 and a 200-day simple moving average of $40.82.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.38). The firm had revenue of $61.55 million for the quarter, compared to the consensus estimate of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. On average, equities research analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.